secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001082554-22-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q3 revenue $516M (+16% YoY); net income $239M (+47%)
------------------------------------------------------------------------

- Net income per diluted share $4.91; Tyvaso revenues $257.7M (+57% YoY) driven by Tyvaso DPI launch.
- Tyvaso achieved $1B annual run-rate; management targets 6,000 patients on Tyvaso by year-end.
- R&D expense $66.1M (-17% YoY) due to fair value adjustments; PERFECT study discontinued per DSMC.
- TETON 2 study of Tyvaso in IPF enrolled first patient October 2022; TETON 1 enrollment ongoing.
- Remunity Pump launched patient-filled version in September 2022 for monthly cassette shipments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/0001082554-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/uthr-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001082554-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer